Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 80 50 versus SECTRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 80 50 versus SECTRAL.
INDERIDE LA 80/50 vs SECTRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of propranolol (non-selective beta-blocker) and hydrochlorothiazide (thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Selective beta-1 adrenergic receptor antagonist; negative chronotropic and inotropic effects, reduces cardiac output, decreases renin release.
One capsule orally once daily, containing propranolol hydrochloride 80 mg (immediate release) and hydrochlorothiazide 50 mg. May be titrated based on response, with maximum propranolol dose 640 mg/day and maximum hydrochlorothiazide dose 50 mg/day.
Adult: 200–400 mg orally once daily, initially; may increase to 400–800 mg daily in divided doses (e.g., 200 mg twice daily). Maximum 800 mg/day. Route: Oral.
None Documented
None Documented
Propranolol: 3-6 hours (poor metabolizers up to 10 hours). Hydrochlorthiazide: 6-15 hours (prolonged in renal impairment).
Terminal elimination half-life: 8-13 hours; clinically, this supports once-daily dosing, but steady-state is achieved within 2-3 days.
Renal elimination of propranolol and hydrochlorthiazide: propranolol is extensively metabolized in the liver, <1% excreted unchanged in urine; hydrochlorthiazide is excreted unchanged in urine (≥95% renal).
Renal: ~30-40% unchanged; biliary/fecal: ~20-30% as metabolites and parent compound; total renal clearance accounts for 50-70% of elimination.
Category C
Category C
Beta Blocker and Thiazide Diuretic
Beta Blocker